Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of Non-Hodgkin’s Lymphoma. Vol. 9, Medical sciences (Basel, Switzerland). 2021. DOI: 10.3390/medsci9010005 DOI: https://doi.org/10.3390/medsci9010005

Mafra A, Laversanne M, Gospodarowicz M, et al. Global patterns of non-Hodgkin lymphoma in 2020. Int J Cancer. 2022;151(9):1474–1481. DOI: https://doi.org/10.1002/ijc.34163 PMID:35695282 DOI: https://doi.org/10.1002/ijc.34163

AIOM AIRTUM. I numeri del cancro in Italia 2023. 2023 Online https://www.aiom.it/i-numeri-del-cancro-in-italia/ (Accessed October 2024)

Castillo JJ, Olszewski AJ, Cronin AM, et al. Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014;123(25):3999–4000. DOI: https://doi.org/10.1182/blood-2014-05-574871 PMID:24948623 DOI: https://doi.org/10.1182/blood-2014-05-574871

Buske C, Leblond V, Dimopoulos M, Kimby E, Jäger U, Dreyling M. Waldenström’s macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013;24(SUPPL.6). DOI: 10.1093/annonc/mdt298 DOI: https://doi.org/10.1093/annonc/mdt298

Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. Br J Cancer. 2015;112(9):1575–1584. DOI: https://doi.org/10.1038/bjc.2015.94 PMID:25867256 DOI: https://doi.org/10.1038/bjc.2015.94

Li S, Liu J, Bowers C, et al. Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma. Support Care Cancer. 2020;28(1):113–122. DOI: https://doi.org/10.1007/s00520-019-04795-0 PMID:30993450 DOI: https://doi.org/10.1007/s00520-019-04795-0

Kenzik KM, Mehta A, Richman JS, et al. Congestive heart failure in older adults diagnosed with follicular lymphoma: A population-based study. Cancer. 2018;124(21):4221–4230. DOI: https://doi.org/10.1002/cncr.31695 PMID:30303522 DOI: https://doi.org/10.1002/cncr.31695

Kenzik KM, Williams GR, Bhakta N, et al. Healthcare utilization and spending among older patients diagnosed with Non-Hodgkin lymphoma. J Geriatr Oncol. 2021;12(8):1225–1232. DOI: https://doi.org/10.1016/j.jgo.2021.06.006 PMID:34176753 DOI: https://doi.org/10.1016/j.jgo.2021.06.006

Zakeri M, Li J, Sansgiry SS, et al. Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: analysis of national survey data. J Manag Care Spec Pharm. 2023;29(5):480–489. DOI: https://doi.org/10.18553/jmcp.2023.29.5.480 PMID:37121258 DOI: https://doi.org/10.18553/jmcp.2023.29.5.480

Mounie M, Costa N, Conte C, et al. Costs of Hodgkin and Non-Hodgkin Lymphoma in France: Results on the Basis of the French National Health Insurance Database. Value Health. 2018;21:S25. DOI: https://doi.org/10.1016/j.jval.2018.04.157 DOI: https://doi.org/10.1016/j.jval.2018.04.157

Zucca E, Arcaini L, Buske C, et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17-29. https://doi.org/10.1016/j.annonc.2019.10.010 PMID:31912792 DOI: https://doi.org/10.1016/j.annonc.2019.10.010

Ardeshna KM, Smith P, Norton A, et al; British National Lymphoma Investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516–522. DOI: https://doi.org/10.1016/S0140-6736(03)14110-4 PMID:12932382 DOI: https://doi.org/10.1016/S0140-6736(03)14110-4

Ministero della Salute. Il flusso informativo SDO. Online https://www.salute.gov.it/portale/assistenzaOspedaliera/dettaglioContenutiAssistenzaOspedaliera.jsp?lingua=italiano&id=1232&area=ricoveriOspedalieri&menu=rilevazione (Accessed October 2024)

INPS. Osservatorio sulle pensioni erogate dall’INPS. Online https://servizi2.inps.it/servizi/osservatoristatistici/6 (Accessed October 2024)

Russo S, Mariani TT, Migliorini R, et al. The economic burden of musculoskeletal disorders on the Italian social security pension system estimated by a Monte Carlo simulation. Reumatismo. 2015;67(2):45–56. DOI: https://doi.org/10.4081/reumatismo.2015.811 PMID:26492962 DOI: https://doi.org/10.4081/reumatismo.2015.811

Cerhan JR, Habermann TM. Epidemiology of marginal zone lymphoma. Ann Lymphoma. 2021;5:5. DOI: https://doi.org/10.21037/aol-20-28 PMID:33829216 DOI: https://doi.org/10.21037/aol-20-28

Sant M, Minicozzi P, Mounier M, et al; EUROCARE-5 Working Group. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15(9):931–942. DOI: https://doi.org/10.1016/S1470-2045(14)70282-7 PMID:25030467 DOI: https://doi.org/10.1016/S1470-2045(14)70282-7

Darbà J, Marsà A. Burden of Hodgkin and non-Hodgkin lymphoma in Spain over a 10-year period: productivity losses due to premature mortality. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):87–92.DOI: https://doi.org/10.1080/14737167.2020.1769478 PMID:32450710 DOI: https://doi.org/10.1080/14737167.2020.1769478

Cai W, Zeng Q, Zhang X, et al. Trends Analysis of Non-Hodgkin Lymphoma at the National, Regional, and Global Level, 1990–2019: Results From the Global Burden of Disease Study 2019. Front Med (Lausanne). 2021;8:738693. DOI: https://doi.org/10.3389/fmed.2021.738693 PMID:34631756 DOI: https://doi.org/10.3389/fmed.2021.738693

Miranda-Filho A, Piñeros M, Znaor A,et al. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control. 2019;30(5):489–499. DOI: https://doi.org/10.1007/s10552-019-01155-5 PMID:30895415 DOI: https://doi.org/10.1007/s10552-019-01155-5

Rotbain EC, Rostgaard K, Andersen MA, et al. Healthcare Utilization and Comorbidity in Chronic Lymphocytic Leukemia. Clin Epidemiol. 2021;13:1155–1165. DOI: https://doi.org/10.2147/CLEP.S337495 PMID:35002328 DOI: https://doi.org/10.2147/CLEP.S337495

Pfeil AM, Imfeld P, Pettengell R, et al. Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD). Ann Hematol. 2015;94(3):421–429. DOI: https://doi.org/10.1007/s00277-014-2217-7 PMID:25219890 DOI: https://doi.org/10.1007/s00277-014-2217-7

Lutz C, Feiten S, Chakupurakal G, et al. Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic. BMC Immunol. 2023;24(1):2. DOI: https://doi.org/10.1186/s12865-022-00536-x PMID:36631764 DOI: https://doi.org/10.1186/s12865-022-00536-x

Johnson PC, Yi A, Horick N, et al. Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma. Oncologist. 2021;26(11):965–973. DOI: https://doi.org/10.1002/onco.13915 PMID:34327767 DOI: https://doi.org/10.1002/onco.13915

Chanan-Khan A, Yang K, Liu S, et al. Real-World Disease Burden, Costs and Resource Utilization of Hospital-Based Care Among Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia: Disparities and Risk Factors. Blood. 2021;138(Supplement 1). DOI: 10.1182/blood-2021-148633 DOI: https://doi.org/10.1182/blood-2021-148633

Kabadi SM, Goyal RK, Nagar SP, et al. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Cancer Med. 2019;8(8):3803–3810. DOI: https://doi.org/10.1002/cam4.2268 PMID:31144473 DOI: https://doi.org/10.1002/cam4.2268

Rosand CB, Valla K, Flowers CR, et al. Effective management strategies for patients with marginal zone lymphoma. Future Oncol. 2018;14(12):1213–1222. DOI: https://doi.org/10.2217/fon-2017-0480 PMID:29260925 DOI: https://doi.org/10.2217/fon-2017-0480

Sarosiek S, Treon SP, Castillo JJ. Reducing treatment toxicity in Waldenström macroglobulinemia. Expert Opin Drug Saf. 2021;20(6):669–676. DOI: https://doi.org/10.1080/14740338.2021.1897565 PMID:33645373 DOI: https://doi.org/10.1080/14740338.2021.1897565